Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
EMERYVILLE, Calif., April 27, 2017 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2017, after the market close, and will host a corporate update conference call and webcast on Thursday, May 4th, at 4:30 PM Eastern Time.
Thursday, May 4th @ 4:30 PM Eastern Time/1:30 PM Pacific Time
| Toll Free: | 888-287-5516 |
| International: | 719-325-2436 |
| Conference ID: | 2588025 |
| Webcast: | http://public.viavid.com/index.php?id=123895 |
Replays, available through May 18, 2017:
| Domestic: | 844-512-2921 |
| International: | 412-317-6671 |
| Replay PIN: | 2588025 |
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
